251 related articles for article (PubMed ID: 32416764)
1. Tumour-specific fluorescence-guided surgery for pancreatic cancer using panitumumab-IRDye800CW: a phase 1 single-centre, open-label, single-arm, dose-escalation study.
Lu G; van den Berg NS; Martin BA; Nishio N; Hart ZP; van Keulen S; Fakurnejad S; Chirita SU; Raymundo RC; Yi G; Zhou Q; Fisher GA; Rosenthal EL; Poultsides GA
Lancet Gastroenterol Hepatol; 2020 Aug; 5(8):753-764. PubMed ID: 32416764
[TBL] [Abstract][Full Text] [Related]
2. Optimal Dosing Strategy for Fluorescence-Guided Surgery with Panitumumab-IRDye800CW in Head and Neck Cancer.
Nishio N; van den Berg NS; van Keulen S; Martin BA; Fakurnejad S; Zhou Q; Lu G; Chirita SU; Kaplan MJ; Divi V; Colevas AD; Rosenthal EL
Mol Imaging Biol; 2020 Feb; 22(1):156-164. PubMed ID: 31054001
[TBL] [Abstract][Full Text] [Related]
3. Molecular fluorescence-guided surgery of peritoneal carcinomatosis of colorectal origin: a single-centre feasibility study.
Harlaar NJ; Koller M; de Jongh SJ; van Leeuwen BL; Hemmer PH; Kruijff S; van Ginkel RJ; Been LB; de Jong JS; Kats-Ugurlu G; Linssen MD; Jorritsma-Smit A; van Oosten M; Nagengast WB; Ntziachristos V; van Dam GM
Lancet Gastroenterol Hepatol; 2016 Dec; 1(4):283-290. PubMed ID: 28404198
[TBL] [Abstract][Full Text] [Related]
4. Metastatic and sentinel lymph node mapping using intravenously delivered Panitumumab-IRDye800CW.
Krishnan G; van den Berg NS; Nishio N; Juniper G; Pei J; Zhou Q; Lu G; Lee YJ; Ramos K; Iagaru AH; Baik FM; Colevas AD; Martin BA; Rosenthal EL
Theranostics; 2021; 11(15):7188-7198. PubMed ID: 34158844
[No Abstract] [Full Text] [Related]
5. Safety of panitumumab-IRDye800CW and cetuximab-IRDye800CW for fluorescence-guided surgical navigation in head and neck cancers.
Gao RW; Teraphongphom N; de Boer E; van den Berg NS; Divi V; Kaplan MJ; Oberhelman NJ; Hong SS; Capes E; Colevas AD; Warram JM; Rosenthal EL
Theranostics; 2018; 8(9):2488-2495. PubMed ID: 29721094
[No Abstract] [Full Text] [Related]
6. Panitumumab-IRDye800CW for Fluorescence-Guided Surgical Resection of Colorectal Cancer.
Marston JC; Kennedy GD; Lapi SE; Hartman YE; Richardson MT; Modi HM; Warram JM
J Surg Res; 2019 Jul; 239():44-51. PubMed ID: 30798171
[TBL] [Abstract][Full Text] [Related]
7. Effect of Formalin Fixation for Near-Infrared Fluorescence Imaging with an Antibody-Dye Conjugate in Head and Neck Cancer Patients.
Kapoor S; Lu G; van den Berg NS; Krishnan G; Pei J; Zhou Q; Martin BA; Baik FM; Rosenthal EL; Nishio N
Mol Imaging Biol; 2021 Apr; 23(2):270-276. PubMed ID: 33078373
[TBL] [Abstract][Full Text] [Related]
8. The Sentinel Margin: Intraoperative
van Keulen S; Nishio N; Birkeland A; Fakurnejad S; Martin B; Forouzanfar T; Cunanan K; Colevas AD; S van den Berg N; Rosenthal E
Clin Cancer Res; 2019 Aug; 25(15):4656-4662. PubMed ID: 31142505
[TBL] [Abstract][Full Text] [Related]
9. Sensitivity and Specificity of Cetuximab-IRDye800CW to Identify Regional Metastatic Disease in Head and Neck Cancer.
Rosenthal EL; Moore LS; Tipirneni K; de Boer E; Stevens TM; Hartman YE; Carroll WR; Zinn KR; Warram JM
Clin Cancer Res; 2017 Aug; 23(16):4744-4752. PubMed ID: 28446503
[No Abstract] [Full Text] [Related]
10. Intraoperative Molecular Fluorescence Imaging of Pancreatic Cancer by Targeting Vascular Endothelial Growth Factor: A Multicenter Feasibility Dose-Escalation Study.
Mulder BGS; Koller M; Duiker EW; Sarasqueta AF; Burggraaf J; Meijer VE; Vahrmeijer AL; Hoogwater FJH; Bonsing BA; van Dam GM; Mieog JSD; Pranger BK
J Nucl Med; 2023 Jan; 64(1):82-89. PubMed ID: 35680414
[TBL] [Abstract][Full Text] [Related]
11. Safety and effectiveness of SGM-101, a fluorescent antibody targeting carcinoembryonic antigen, for intraoperative detection of colorectal cancer: a dose-escalation pilot study.
Boogerd LSF; Hoogstins CES; Schaap DP; Kusters M; Handgraaf HJM; van der Valk MJM; Hilling DE; Holman FA; Peeters KCMJ; Mieog JSD; van de Velde CJH; Farina-Sarasqueta A; van Lijnschoten I; Framery B; Pèlegrin A; Gutowski M; Nienhuijs SW; de Hingh IHJT; Nieuwenhuijzen GAP; Rutten HJT; Cailler F; Burggraaf J; Vahrmeijer AL
Lancet Gastroenterol Hepatol; 2018 Mar; 3(3):181-191. PubMed ID: 29361435
[TBL] [Abstract][Full Text] [Related]
12. Targeting tumour-associated macrophages with CCR2 inhibition in combination with FOLFIRINOX in patients with borderline resectable and locally advanced pancreatic cancer: a single-centre, open-label, dose-finding, non-randomised, phase 1b trial.
Nywening TM; Wang-Gillam A; Sanford DE; Belt BA; Panni RZ; Cusworth BM; Toriola AT; Nieman RK; Worley LA; Yano M; Fowler KJ; Lockhart AC; Suresh R; Tan BR; Lim KH; Fields RC; Strasberg SM; Hawkins WG; DeNardo DG; Goedegebuure SP; Linehan DC
Lancet Oncol; 2016 May; 17(5):651-62. PubMed ID: 27055731
[TBL] [Abstract][Full Text] [Related]
13. Fluorescence-guided imaging for resection margin evaluation in head and neck cancer patients using cetuximab-800CW: A quantitative dose-escalation study.
Voskuil FJ; de Jongh SJ; Hooghiemstra WTR; Linssen MD; Steinkamp PJ; de Visscher SAHJ; Schepman KP; Elias SG; Meersma GJ; Jonker PKC; Doff JJ; Jorritsma-Smit A; Nagengast WB; van der Vegt B; Robinson DJ; van Dam GM; Witjes MJH
Theranostics; 2020; 10(9):3994-4005. PubMed ID: 32226534
[TBL] [Abstract][Full Text] [Related]
14. Safety and tolerability of the first-in-class agent CPI-613 in combination with modified FOLFIRINOX in patients with metastatic pancreatic cancer: a single-centre, open-label, dose-escalation, phase 1 trial.
Alistar A; Morris BB; Desnoyer R; Klepin HD; Hosseinzadeh K; Clark C; Cameron A; Leyendecker J; D'Agostino R; Topaloglu U; Boteju LW; Boteju AR; Shorr R; Zachar Z; Bingham PM; Ahmed T; Crane S; Shah R; Migliano JJ; Pardee TS; Miller L; Hawkins G; Jin G; Zhang W; Pasche B
Lancet Oncol; 2017 Jun; 18(6):770-778. PubMed ID: 28495639
[TBL] [Abstract][Full Text] [Related]
15. Neoadjuvant cemiplimab for resectable hepatocellular carcinoma: a single-arm, open-label, phase 2 trial.
Marron TU; Fiel MI; Hamon P; Fiaschi N; Kim E; Ward SC; Zhao Z; Kim J; Kennedy P; Gunasekaran G; Tabrizian P; Doroshow D; Legg M; Hammad A; Magen A; Kamphorst AO; Shareef M; Gupta NT; Deering R; Wang W; Wang F; Thanigaimani P; Mani J; Troncoso L; Tabachnikova A; Chang C; Akturk G; Buckup M; Hamel S; Ioannou G; Hennequin C; Jamal H; Brown H; Bonaccorso A; Labow D; Sarpel U; Rosenbloom T; Sung MW; Kou B; Li S; Jankovic V; James N; Hamon SC; Cheung HK; Sims JS; Miller E; Bhardwaj N; Thurston G; Lowy I; Gnjatic S; Taouli B; Schwartz ME; Merad M
Lancet Gastroenterol Hepatol; 2022 Mar; 7(3):219-229. PubMed ID: 35065058
[TBL] [Abstract][Full Text] [Related]
16. EGFR-targeted intraoperative fluorescence imaging detects high-grade glioma with panitumumab-IRDye800 in a phase 1 clinical trial.
Zhou Q; van den Berg NS; Rosenthal EL; Iv M; Zhang M; Vega Leonel JCM; Walters S; Nishio N; Granucci M; Raymundo R; Yi G; Vogel H; Cayrol R; Lee YJ; Lu G; Hom M; Kang W; Hayden Gephart M; Recht L; Nagpal S; Thomas R; Patel C; Grant GA; Li G
Theranostics; 2021; 11(15):7130-7143. PubMed ID: 34158840
[No Abstract] [Full Text] [Related]
17. Fluorescence- and multispectral optoacoustic imaging for an optimized detection of deeply located tumors in an orthotopic mouse model of pancreatic carcinoma.
Napp J; Stammes MA; Claussen J; Prevoo HAJM; Sier CFM; Hoeben FJM; Robillard MS; Vahrmeijer AL; Devling T; Chan AB; de Geus-Oei LF; Alves F
Int J Cancer; 2018 May; 142(10):2118-2129. PubMed ID: 29277891
[TBL] [Abstract][Full Text] [Related]
18. Determination of Tumor Margins with Surgical Specimen Mapping Using Near-Infrared Fluorescence.
Gao RW; Teraphongphom NT; van den Berg NS; Martin BA; Oberhelman NJ; Divi V; Kaplan MJ; Hong SS; Lu G; Ertsey R; Tummers WSFJ; Gomez AJ; Holsinger FC; Kong CS; Colevas AD; Warram JM; Rosenthal EL
Cancer Res; 2018 Sep; 78(17):5144-5154. PubMed ID: 29967260
[TBL] [Abstract][Full Text] [Related]
19. Cisplatin and fluorouracil with or without panitumumab in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck (SPECTRUM): an open-label phase 3 randomised trial.
Vermorken JB; Stöhlmacher-Williams J; Davidenko I; Licitra L; Winquist E; Villanueva C; Foa P; Rottey S; Skladowski K; Tahara M; Pai VR; Faivre S; Blajman CR; Forastiere AA; Stein BN; Oliner KS; Pan Z; Bach BA;
Lancet Oncol; 2013 Jul; 14(8):697-710. PubMed ID: 23746666
[TBL] [Abstract][Full Text] [Related]
20. Ramucirumab plus pembrolizumab in patients with previously treated advanced non-small-cell lung cancer, gastro-oesophageal cancer, or urothelial carcinomas (JVDF): a multicohort, non-randomised, open-label, phase 1a/b trial.
Herbst RS; Arkenau HT; Santana-Davila R; Calvo E; Paz-Ares L; Cassier PA; Bendell J; Penel N; Krebs MG; Martin-Liberal J; Isambert N; Soriano A; Wermke M; Cultrera J; Gao L; Widau RC; Mi G; Jin J; Ferry D; Fuchs CS; Petrylak DP; Chau I
Lancet Oncol; 2019 Aug; 20(8):1109-1123. PubMed ID: 31301962
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
